BARDA: House vs. Senate

Earlier this month, Representative Mike Rogers (R-MI) submitted the House version (H.R.5533) of the `Biodefense and Pandemic Vaccine and Drug Development Act of 2006' (BARDA). The bill was introduced in the Senate by Senator Richard Burr (R-NC) (S.2564). The two bills are essentially the same with the exception of two controversial sections included in the Senate, but not the House version. Section 5: Orphan Drug Market Exclusivity for Countermeasures Products and Section 7: Collaboration and Coordination. The Market Exclusivity section Amends the Federal Food, Drug, and Cosmetic Act to extend the period of market exclusivity from seven years to ten years for certain new drugs, antibiotics, or anti-infective drugs to treat a rare disease or condition caused by a biological agent, toxin, chemical, radiological, or nuclear agent that is deemed by the Secretary to be a material threat to the United States. The Collaboration and Coordination section provides an antitrust exemption for: (1) meetings and consultations held by the Secretary among persons engaged in the development of countermeasures or pandemic or epidemic products; and (2) agreements resulting from such meetings. See the extended entry for the full text of Sections 5 and 7.

Read more

IAEA Secretary General elBaradei Supports Indian-US Nuclear Deal.

In an op-ed in last Wednesday’s Washington Post, IAEA Secretary General Mohammad elBaradei endorsed the US-India nuclear deal without reservation. The Secretary makes several good points but he fails to demonstrate his assertion that the deal will help reach his own objectives.

Read more